Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Mesalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Mesalazine Dr Falk Pharma enemas contain the active substance mesalazine, an anti-inflammatory agent used to treat inflammatory bowel disease. Mesalazine Dr Falk Pharma enemas are used for: − the treatment of mild episodes of an inflammatory disease in parts of the colon and the rectum (back passage) known by doctors as ulcerative colitis or ulcerative proctitis.
e Mesalazine Dr Falk Pharma 2 g enemas Do not use Mesalazine Dr Falk Pharma enemas − If you are allergic to mesalazine, salicylic acid, salicylates such as acetylsalicylic acid (e.g., aspirin) or any of the other ingredients of this medicine (listed in section 6). − If you have a serious liver or kidney disease. Warnings and precautions Talk to your doctor or pharmacist before using this medicine: − If you have a history of problems with your lungs, particularly if you suffer from bronchial asthma. − If you have a history of allergy to sulphasalazine, a substance related to mesalazine. − If you suffer with problems of your liver. − If you suffer with problems of your kidney. − If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine. Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless.
Further precautions During treatment your doctor may want to keep you under close medical supervision, and you may need to have regular blood and urine tests. Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine. Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4. If you experience strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears contact your doctor immediately. Other medicines and Mesalazine Dr Falk Pharma enemas Tell your doctor if you take or use any of the medicines mentioned below as the effects of these medicines may change (interactions): − −
Azathioprine, 6-mercaptopurine or thioguanine (medicines used to treat immune disorders). Certain agents that inhibit blood clotting (medicines for thrombosis or to thin your blood, e.g., warfarin)
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. It may still be alright for you to use this medicine and your doctor will be able to decide what is suitable for you.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should only use this medicine during pregnancy if your doctor tells you to. You should also only use this medicine during breast-feeding if your doctor tells you to, as this medicine may pass into breast milk.
Driving and using machines There are no effects on the ability to drive and use machines. Mesalazine Dr Falk Pharma enema contains potassium metabisulphite and sodium benzoate Potassium metabisulphite may rarely cause severe hypersensitivity reactions and bronchospasm. This medicinal product contains 60 mg sodium benzoate in each Mesalazine Dr Falk Pharma enema. Sodium benzoate may cause local irritation.
Mesalazine Dr Falk Pharma 2 g enemas Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Method of administration This medicine may only be used rectally, so it has to be inserted through the anus. Do NOT take by mouth. Dosage Adults and elderly: The recommended dose is one enema once a day, at bedtime. For the best results empty your bowels before using the enema. –
–
Shake the bottle well for at least 30 seconds before use to ensure thorough mixing. Remove the protective cap. Hold the container upright to avoid spillage. Lie on your left side with your left leg stretched out and your right knee bent for balance. If this is not convenient, then lie on your right side with your right leg stretched out and your left leg bent for balance to apply the enema but turn to your left side after application. Insert the lubricated applicator deep into your rectum. Keep the bottle pointed towards your navel. Tip the bottle slightly downwards and then squeeze it slowly and evenly. Once the bottle is empty, slowly remove the applicator. Lie on your left side for at least 30 minutes to enable the medicine to spread evenly through the bowel. Try to retain the enema all night.
Use in children There is little experience and only limited documentation for an effect in children. Duration of treatment The treatment of acute episodes of ulcerative colitis usually lasts 8 weeks. Your doctor will decide how long you need to continue the treatment with this medicine. This will depend on your condition. To obtain the maximum benefit from this medicine, you should use Mesalazine Dr Falk Pharma enemas regularly and consistently, as directed. If you think your Mesalazine Dr Falk Pharma enemas are too strong or too weak, talk to your doctor. If you use more Mesalazine Dr Falk Pharma enemas than you should Contact a doctor if you are in doubt, so he or she can decide what to do. If you use too many enemas on one occasion, just use your next dose as prescribed. Do not use a smaller amount. If you forget to use Mesalazine Dr Falk Pharma enemas Do not use a larger than normal dose of Mesalazine Dr Falk Pharma enema next time, but continue treatment at the prescribed dosage. If you stop using Mesalazine Dr Falk Pharma enemas Do not stop using this product until you have talked to your doctor. If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following symptoms after using this medicine, you should contact your doctor and stop using Mesalazine Dr Falk Pharma enemas immediately:
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects you can help provide more information on the safety of this medicine.
Mesalazine Dr Falk Pharma 2 g enemas Keep out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and on the carton. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6.
What Mesalazine Dr Falk Pharma enemas contain The active substance is mesalazine and one enema contains 2g mesalazine. The other ingredients are Carbomer 35 000, disodium edetate, potassium acetate (E261), potassium metabisulphite (E224), purified water, sodium benzoate (E211), xanthan gum (E415). What Mesalazine Dr Falk Pharma enemas look like and contents of the pack Mesalazine Dr Falk Pharma enemas are in a low-density, concertina shaped, polythene bottle with a low-density polythene application nozzle. Mesalazine Dr Falk Pharma enemas are available in packs of 7. Marketing Authorisation Holder Dr Falk Pharma UK Ltd Unit K, Bourne End Business Park, Cores End Road Bourne End, SL8 5AS Tel: 01628 536600 e-mail: [email protected] Manufacturer Dr. Falk Pharma GmbH Leinenweberstrasse 5 79108 Freiburg Germany This leaflet was last revised in 04/2025
The active substance in Mesalazine Dr Falk Pharma 2g Enema (previously known as Salofalk) is mesalazine.
This leaflet reproduces the patient information leaflet approved for Mesalazine Dr Falk Pharma 2g Enema (previously known as Salofalk), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Therapy and prophylaxis of acute attacks of mild ulcerative colitis, especially in the rectum and sigmoid colon and also in the descending colon.
Posology
Adults and the Elderly: 1 enema once a day at bedtime. The action of Mesalazine Dr Falk Pharma enema is enhanced if the patient lies on the left side when introducing the enema. The dosage should be adjusted to suit the progress of the condition. Do not discontinue treatment suddenly.
The treatment of acute episodes of ulcerative colitis usually last 8 weeks.
Paediatric population
There is little experience and only limited documentation for an effect in children.
Method of administration
Rectal
The best results are achieved if the bowels are emptied before administration of the enema.
The patient should be advised to:
- Shake the bottle for 30 seconds.
- Remove the protective cap.
- Hold the bottle at the top and bottom and keep it upright to avoid spillage.
- Lie down comfortably on the left side with the left leg stretched out and the right leg bent. If more convenient, lie on the right side with the right leg stretched out and with the left leg bent. In this case, turn to the left side after application of the enema.
- Insert the applicator deep into the rectum keeping the bottle tipped downwards slightly.
- Slowly squeeze the bottle until empty.
- Slowly withdraw the applicator from the rectum.
- Lie on the left side for at least 30 minutes to allow the contents of the enema to spread.
- If possible, retain the enema all night.
Mesalazine Dr Falk Pharma enema is contraindicated in cases of:
• Hypersensitivity to the active substance, salicylates or any of the excipients listed in section 6.1.
• Severe impairment of renal or hepatic function.
Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip-sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks.
If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, tests should be performed immediately.
Caution is recommended in patients with impaired hepatic function.
Mesalazine should not be used in patients with impaired renal function. Mesalazine-induced renal toxicity should be considered if renal function deteriorates during treatment. If this is the case, Mesalazine Dr Falk Pharma enema should be discontinued immediately.
Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.
Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).
Serious blood dyscrasias have been reported very rarely with mesalazine. Hematological investigations should be performed if patients suffer from unexplained haemorrhages, bruises, purpura, anaemia, fever or pharyngolaryngeal pain. Mesalazine Dr Falk Pharma enema should be discontinued in case of suspected or confirmed blood dyscrasia.
Cardiac hypersensitivity reactions (myocarditis, and pericarditis) induced by mesalazine have been rarely reported. Mesalazine Dr Falk Pharma enema should then be discontinued immediately.
Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment with mesalazine.
Severe cutaneous adverse reactions
Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.
Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.
Idiopathic intracranial hypertension
Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.
Patients with a history of adverse drug reactions to preparations containing sulphasalazine should be kept under close medical surveillance on commencement of a course of treatment with mesalazine. Should the enema cause acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, therapy should be discontinued immediately.
Mesalazine Dr Falk Pharma enemas contain potassium metabisulphite, which may rarely cause severe hypersensitivity reactions and bronchospasm.
This medicinal product contains 60 mg sodium benzoate in each Mesalazine Dr Falk Pharma enema. Sodium benzoate may cause local irritation.
Specific interaction studies have not been performed.
In patients who are concomitantly treated with azathioprine, 6-mercaptopurine or thioguanine, a possible increase in the myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine should be taken into account.
There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.
Pregnancy
There are no adequate data from the use of mesalazine in pregnant women. However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on the pregnancy or on the health of the foetus/newborn child. To date no other relevant epidemiologic data are available. In one single case after long-term use of a high dose mesalazine (2-4g, orally) during pregnancy, renal failure in a neonate was reported.
Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development, parturition or postnatal development.
Mesalazine Dr Falk Pharma enema should only be used during pregnancy if the potential benefit outweighs the possible risk.
Breastfeeding
N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. Only limited experience with mesalazine during lactation in women is available to date. Hypersensitivity reactions such as diarrhoea in the infant cannot be excluded. Therefore, Mesalazine Dr Falk Pharma enema should only be used during breast-feeding if the potential benefit outweighs the possible risk. If the infant develops diarrhoea, breast-feeding should be discontinued.
Mesalazine has no or negligible influence on the ability to drive and use machines.
The following undesirable effects have been observed after administration of mesalazine:
Organ Class System
Frequency According to MedDRA Convention
Common
(≥ 1/100; <1/10)
Rare
(≥ 1/10,000; <1/1,000)
Very rare
(< 1/ 10,000)
Not known
(cannot be estimated from the available data)
Blood and lymphatic system disorders
Altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia)
Nervous system disorders
Headache, dizziness
peripheral neuropathy
Idiopathic intracranial hypertension (see section 4.4)
Cardiac disorders
Myocarditis, Pericarditis
Respiratory, thoracic and mediastinal disorders
Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis)
Gastrointestinal disorders
Abdominal pain, diarrhoea, flatulence, nausea, vomiting, constipation
Acute pancreatitis
Renal and urinary disorders
Impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency
Nephrolithiasis*
Skin and subcutaneous tissue disorders
Rash, pruritus
Photo-sensitivity
Alopecia
Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
Musculo-skeletal and connective tissue disorders
Myalgia, arthralgia
Immune system disorders
Hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis
Hepatobiliary disorders
Changes in liver function parameters (increase in transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis
Reproductive system disorders
Oligospermia (reversible)
* see section 4.4 for further information
Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).
Photosensitivity
More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.
Reporting of suspected adverse reactions
Reporting of suspected reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
There are rare data on overdosage (e.g. intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote and treatment is symptomatic and supportive.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Mesalazine Dr Falk Pharma 2g Enema (previously known as Salofalk). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.